{"schema_version":"secwatch.filing_event.v1","accession":"0001651308-23-000125","form_type":"8-K","ticker":"ONC","cik":"0001651308","company_name":"BeOne Medicines Ltd.","filed_at":"2023-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.719216+00:00","generated_at":"2026-06-12T13:51:03.921962+00:00","sec_items":["1.01","1.02","2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"BeiGene Q2 product revenue $553.7M (+82% YoY); BRUKINSA sales $308M; settles BMS arbitration","bullets":["Settled BMS-Celgene dispute: BMS transfers 23.3M BeiGene shares to BeiGene, no cash payment; arbitration dismissed.","BRUKINSA global sales $308M (+139% YoY); U.S. sales $223.5M (+153% YoY); tislelizumab China sales $149.5M (+42.5% YoY).","Net loss improved to $381.1M from $565.7M YoY; operating leverage driven by 82% revenue growth vs 15% expense growth.","Regained full global rights to TIGIT inhibitor ociperlimab from Novartis; partnered with DualityBio for preclinical ADC.","Cash, equivalents and short-term investments $3.5B at June 30, down from $4.5B at year-end 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001651308-23-000125","json":"https://secwatch.observer/filing/0001651308-23-000125.json","markdown":"https://secwatch.observer/filing/0001651308-23-000125.md","text":"https://secwatch.observer/filing/0001651308-23-000125.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651308/000165130823000125/0001651308-23-000125-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651308/000165130823000125/bgne-20230801.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T13:51:03.921962+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8c51468ed47c4ae7a46292e38acbfe44217fe23b","claim":"BeOne Medicines Ltd. reported the three months ended June 30, 2023 results: revenue $553.7 million, net income $381.1 million, EPS $0.28 per share.","evidence_excerpt":"Report on Form 8-K. --- EX-99.1 (EX-99.1) --- BeiGene Accelerates Global Momentum with Strong Second Quarter 2023 Financial Results • Recorded total product revenue of $554 million in the quarter, an increase of 82% from the prior-year period, driven by increased sales of BRUKINSA® worldwide • Global sales of BRUKINSA totaled $308 million in the quarter, a","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1651308/000165130823000125/0001651308-23-000125-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended June 30, 2023"},{"label":"Revenue","value":"$553.7 million"},{"label":"Net income","value":"$381.1 million"},{"label":"EPS","value":"$0.28 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"a4b3fd89411d07c40211c1a615450517f8a50ff9","claim":"BeOne Medicines Ltd. entered into Settlement and Termination Agreement with Bristol-Myers Squibb Company, Celgene Corporation, Celgene Switzerland LLC, Celgene Kappa Holdings LLC, Celgene Holdings East Corporation, Celgene Logistics Sàrl (effective 2023-08-01).","evidence_excerpt":"On August 1, 2023, BeiGene, Ltd. ( \"BeiGene\") and its wholly-owned indirect subsidiary, BeiGene Switzerland GmbH, signed a Settlement and Termination Agreement (the “Agreement”) with Bristol-Myers Squibb Company (“BMS”), Celgene Corporation, Celgene Switzerland LLC, Celgene Kappa Holdings LLC, Celgene Holdings East Corporation, and Celgene Logistics Sàrl (collectively with BMS, “BMS-Celgene”), relating to the termination of the parties’ ongoing contractual relationships","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1651308/000165130823000125/0001651308-23-000125-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"settlement"},{"label":"Counterparty","value":"Bristol-Myers Squibb Company, Celgene Corporation, Celgene Switzerland LLC, Celgene Kappa Holdings LLC, Celgene Holdings East Corporation, Celgene Logistics Sàrl"},{"label":"Effective","value":"2023-08-01"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}